Uveitis Treatment Market With Major Key Companies AbbVie, Novartis AG, Eyegate Pharmaceuticals, Santen Pharmaceuticals, Allergan

 

Uveitis alludes to aggravation caused in the uvea of the eye. An uvea is the center layer of the eye that comprises of three parts specifically iris, cilliary body, and the choroid. Uveitis is brought about by different factors like fiery illnesses, wounds in the eye, microbial diseases, for example, viral, bacterial, and parasitic contamination or openness to certain poisonous synthetics like solid acids or pesticides. Nonetheless, much of the time the reason for this condition stays obscure. It is likewise observed to impact individuals having a place with the age gathering of 20–50 years. The condition is ordered dependent on the area of irritation in the uvea and is arranged in three kinds including foremost uveitis that causes aggravation in the iris and is the most regularly experienced sort. The other two sorts incorporate transitional uveitis and back uveitis that influences the back choroid part of the uvea. Uveitis can be treated with the assistance of different medications that incorporate corticosteroids, immunosuppressant, monoclonal antibodies, analgesics, and medication plans.

Primary driving factor contributing towards growth of the uveitis treatment market is rising incidence of uveitis. According to a study by American University of Beirut Medical Center in 2015, Uveitis is responsible for 10% of legal blindness in the U.S. and up to 25% of blindness in the developing countries. Moreover, according to a study conducted by F. I. Proctor Foundation, University of California, San Francisco in 2013 suggested that uveitis incidence rate among the U.S. population could be approximated to 24.9 cases per 100,000 people.

Asia Pacific is relied upon to observe a critical development in the worldwide uveitis treatment market and this can be credited to expanding number of provincial players zeroing in on improvement of biologics for the treatment of uveitis. For example, Santen Pharmaceuticals got U.S. FDA endorsement for its new medication in April 2017, for the treatment of non-irresistible uveitis of the back fragment.

Some of the major players operating in the uveitis treatment market are AbbVie, Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Santen Pharmaceuticals, Allergan Plc, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., and Alimera Sciences.